Biom’up Appoints Thierry Darnis as Global Vice President, Manufacturing & Engineering

Thierry Darnis, 54, brings extensive experience in the management of major manufacturing sites for
medical devices, acquired at top-tier global companies. At Medtronic and CR Bard he managed plants
pursuing a successful twofold objective of increasing volumes, while optimizing costs. Before joining
Biom’up, Thierry Darnis was deputy chief executive officer of Sofradim Production, a subsidiary of
Medtronic plc (Dublin, Ireland/Minnesota, USA), in charge of the Trevoux plant (340 employees) that he
managed for more than 12 years. He has a Ph.D. in Life and Health Sciences, specialized in
Biomaterials, from the University of Bordeaux II.
At Biom’up, Thierry Darnis will be tasked with completing the production scale-up for HemoblastTM
Bellows while reinforcing team structures in order to meet production targets. His strategic
understanding and tactical experience acquired over a career of 28 years will help assist the existing
teams during the phase of intense growth in production.
This appointment follows the recent announcement of a new production plant to be completed in 2020
on the occasion of the visit to Biom’up of David Kimelfeld, President of Lyon Metropole. This new plant
will make it possible to increase production capacity for HemoblastTM Bellows in line with sales targets.
Etienne Binant, Chief Executive Officer of Biom’up, said: “Thierry Darnis’ arrival to take charge of
production and scale up is excellent news for Biom’up and its teams. His experience in managing large
manufacturing units, his analytical rigor and thorough understanding of operational issues related to
scale up and production will allow Biom’up to advance to a new level. Manufacturing is critical to our
growth strategy, requiring permanent support of and relations with the marketing and business
development teams.”
Thierry Darnis said: “I am delighted to become a member of Biom’up’s teams and contribute my
experience at this critical juncture of the company’s growth. The company’s goal to become a major
global player in the surgical hemostasis market, as well as the strong ambitions of its stakeholders are
extremely compelling. The launch of this new plant by 2020 in conjunction with scaling up existing
production facilities to keep pace with growing sales, represents a truly stimulating and exciting
challenge. I would like to thank in advance Biom’up’s teams for their welcome. I am convinced that
together, building on the strength of their engagement, we will be able to achieve our goals”.
Contacts
Biom’up
Press
Florence Drory
f.drory@biomup.com
+33 (0)6 95 91 12 86
NewCap
Investors
Tristan Roquet Montégon
biomup@newcap.eu
+33 (0)1 44 71 00 16
LifeSci Advisors
Investors
Hans Herklots
hherklots@lifesciadvisors.com.
+41 79 598 7149
About Biom’up
Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom’up designs hemostatic
products based on patented biopolymers that aim to simplify surgical procedures in numerous
specialties (spine, cardiothoracic, general, orthopedic, plastic) and give patients a better quality of life.
Its flagship product, HEMOBLAST™ Bellows, is a unique hemostatic solution, ready to use (no
preparation time needed, no need to mix, no heat required), usable once or several times during the
surgery. Developed by a world-renowned scientific team, HEMOBLAST™ Bellows has obtained positive
results for all the primary and secondary endpoints of Phase III of its pivotal study involving 412 patients
in the United States. HEMOBLAST™ Bellows obtained its CE Mark in December 2016, and its PMA
(Pre-Market Approval) application was granted by the FDA (Food & Drug Administration) in December
2017. Since its creation, Biom’up has benefited from the support of prominent European investors such
as Bpifrance, Innobio, GIMV, Lundbeckfond, Mérieux Participation, SHAM and ACG, as well as all the
Company’s managers, who have invested €2 million in equity. Biom’up is now listed on Euronext.